Chronic graft-versus-host disease (GVHD) involving the liver most commonly manifests as indolent cholestasis. However, a hepatitic variant of GVHD with marked transaminitis and lobular inflammation on liver biopsy is now well recognized. 1, 2 The pathogenesis of this complication is poorly understood. Here we report a case of hepatitic GVHD with positive autoimmune serology that led to the definition of cytochrome P450 1A2 (CYP1A2) as a target antigen.
A 47-year-old male received a non-myeloablative HLAmatched sibling transplant for acute myeloid leukemia with normal cytogenetics following three cycles of idarubicin, cytarabine and etoposide remission-induction therapy. Conditioning was with fludarabine 50 mg/m 2 and cyclophosphamide 120 mg/m 2 . Both donor and recipient were cytomegalovirus immunoglobulin G positive. Standard cyclosporin A and short-course methotrexate GVHD prophylaxis was used. Initial post transplant course was uneventful, with neutrophil engraftment on day 17, and no acute GVHD. Owing to mixed lymphoid chimerism, cyclosporine was tapered from day 94 post transplant, and a donor leukocyte infusion (DLI) given at day 124 (2 Â 10 6 T-lymphocytes per kilogram recipient body weight). One month following DLI, concomitant with attainment of 100% donor lymphoid chimerism, the patient developed florid oral chronic GVHD and striking elevation of hepatic transaminases (alanine aminotransferase and aspartate aminotransferase peaked at 3604 (R 0-55 IU/l) and 2241 (R 0-45 IU/l), respectively) with relatively minor elevation of hepatic ductal markers (GGT 327, R 0-60 IU/l) ( Figure 1 ). Drug and viral causes of hepatitis were excluded. Liver biopsy demonstrated an acute lobular hepatitis with apoptotic bodies, focally confluent cell loss and sparse inflammatory cell infiltration including scattered plasma cells, a picture similar to an acute presentation of autoimmune hepatitis.
Multiple recipient serum samples at this time demonstrated the presence of a high titer anti-liver microsomal (LM) antibody (titer 1:1280 by indirect immunofluorescence) 3 ( Figure 2a and b) reminiscent of hydralazineinduced hepatitis. 4 This was not present in donor or recipient pre-transplant sera. To identify the liver antigen recognized by the LM-reactive sera, positive samples were tested by immunoblotting using preparations of human liver homogenates. All post transplant sera strongly immunofixed an antigen of approximately 51 kDa (Figure 2c ). Again, neither pre-transplant recipient nor donor sera were reactive. To define the antibody specificity, sera were tested by dot-blotting against 13 recombinant CYP450 proteins. 5 Recipient post transplantation LMpositive samples recognized only CYP1A2 (Figure 2d ). This specificity was confirmed with blocking and inhibition experiments (Figure 2e ). To determine if CYP1A2 reactivity was due to differences in the coding sequence of the CYP1A2 gene between donor and recipient, genomic sequencing of the entire coding region of CYP1A2 was performed (primer sequences and polymerase chain reaction conditions are available upon request). We did not identify any coding variants present in the recipient but not the donor.
Oral prednisolone (50 mg/day) resulted in brisk improvement in hepatitis and oral chronic GVHD, and was ceased at 12 months post transplant. The patient remains well with no further GVHD, 100% donor lymphoid chimerism and normal liver function studies over 3 years post transplant. This is the first description of a putative target antigen in hepatitic GVHD. The development of anti-CYP1A2 antibodies concomitant with hepatitis similar to the autoimmune hepatitis seen in the APECED syndrome (autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy) 6 and hydralazine-induced hepatitis, 7 in which CYP1A2 is an autoantigen, suggest that the identified antibodies are pathogenic, and CYP1A2 is an important target of immune responses in this case. It has been shown that cytochromes migrate in vesicles to the surface hepatocytes where they act as targets for autoantibodies. 8 The mechanism driving the anti-CYP1A2 immune response in this case is unclear, but does not appear to be a CYP1A2 coding polymorphism acting as a minor histocompatibility antigen. The appearance of an autoimmune-like syndrome after withdrawal of cyclosporine is reminiscent of cyclosporine-induced autologous GVHD, in which cyclosporine therapy and preparative conditioning regimens result in abnormal thymic and peripheral T-cell tolerance, allowing the aberrant recognition of self-antigens. 9 Induction of hepatic autoimmune-like responses have been described in liver transplant recipients receiving calcineurin inhibitors, 10 and it is possible that cyclosporine facilitated an autoimmune-type response in this case. Importantly, the appearance of hepatitis concomitant with attainment of full-donor lymphoid chimerism strongly suggests that the 'autoreactive' lymphoid cells were of donor origin, although clinical samples were not available to formally demonstrate this.
Evaluation of liver dysfunction post allo-hematopoietic cell transplant requires the careful consideration and exclusion of drug, toxin and viral causes of hepatitis and cholestasis, before a diagnosis of GVHD and the administration of immunosuppressive therapy. Previous reports of hepatitic GVHD have not, to our knowledge, incorporated autoantibody testing. The present case suggests that these simple tests may both aid differential diagnosis and clinical management, as well as providing further insights into the pathogenesis of this complication. 
